Anti-Measles Virus IgG (MV IgG) Kit ELISA

N° du produit ABIN996993

Ce kit ELISA Measles Virus est un kit ELISA Colorimetric conçu pour quantifier Measles Virus .

Aperçu rapide pour Anti-Measles Virus IgG (MV IgG) Kit ELISA (ABIN996993)

Antigène: Anti-Measles Virus IgG (MV IgG)

Reactivité: Measles Virus

Méthode de détection: Colorimetric

Type de méthode: Competition ELISA

Application: ELISA

Détail du produit

Fonction: Measles IgG Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the detection and quantitative determination of IgG antibodies to Measles (Rubeola) virus in human sera. Individual serum specimens may be used for the determination of immune status. Paired sera, acute and convalescent, may be used to demonstrate seroconversion or a significant rise in antibody as an aid in the diagnosis of recent or current infection.

Analytical Method: Quantitative

Specificité: 99.3%

Sensibilité: 91.0%

Information d'application

Volume d'échantillon: 10 μL

Durée du test: 1 - 2 h

Plaque: Pre-coated

Restrictions: For Research Use only

Stockage

Stock: 4 °C

Date de péremption: 12-14 months

Détail du antigène

Antigène: Anti-Measles Virus IgG (MV IgG)

Autre désignation: Measles IgG

Classe de substances: Antibody

Sujet: Since the introduction of a measles virus vaccine, the U.S. has mounted an effective immunization program which has essentially eliminated measles as a major childhood disease. However, as a result of vaccine failure or the failure to be vaccinated, a recent and persistent shift in the susceptible population towards young adults has been recorded. In the case of measles, severity of illness and mortality rates are highest among adults. Thus, serology has become increasingly important as a tool for determining the immune status of the young adult population entering college or the military. In addition, the linkage between measles infection and premature delivery or spontaneous abortion supports screening pregnant mothers for susceptibility.

Although measles has been recognized as a disease for over two thousand years, a description of its epidemiology first appeared in a paper by Panum in 1849. In his study of an epidemic in the Faroe Islands, Panum observed that measles had an incubation period of two weeks and was contagious but that lifelong immunity followed primary infection.
Over 100 years later, in 1963, the first live measles vaccine was licensed in the United States. Vaccine development was made possible by Enders and Peebles' discovery, in 1954, that the virus could be successfully grown in an in vitro cell culture system. The success of the vaccine program is evident by the precipitous drop in the annual incidence. Classified as a paramyxovirus, measles produces a highly contagious respiratory infection. The disease is spread during the prodromal phase through direct contact with respiratory secretions in the form of droplets. Ironically, because of the low incidence of measles, younger physicians often diagnose the illness late in infection after the patient has exposed others. This has resulted in small isolated miniepidemics among the susceptible population.
Several diseases in addition to Measles have been associated but not causally linked to measles virus. This list includes subacute sclerosing panencephalitis (SSPE), systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Patients with SSPE, a chronic degenerative neurologic disease, have documented high levels of antibody to measles virus. However, for SLE and MS there is less pronounced but statistically significant elevation in antibody levels. The significance or role of measles virus infection in these disease states is unknown at the present time.
Since the presence of circulating IgG antibody to measles virus is indicative of previous infection or vaccination, screening the young adult population about to enter college or the military, pregnant women, and other individuals at risk, for seropositivity, is a valuable tool for determining their immune status.